229 related articles for article (PubMed ID: 21134964)
1. Native properdin binds to Chlamydia pneumoniae and promotes complement activation.
Cortes C; Ferreira VP; Pangburn MK
Infect Immun; 2011 Feb; 79(2):724-31. PubMed ID: 21134964
[TBL] [Abstract][Full Text] [Related]
2. Properdin Pattern Recognition on Proximal Tubular Cells Is Heparan Sulfate/Syndecan-1 but Not C3b Dependent and Can Be Blocked by Tick Protein Salp20.
Lammerts RGM; Talsma DT; Dam WA; Daha MR; Seelen MAJ; Berger SP; van den Born J
Front Immunol; 2020; 11():1643. PubMed ID: 32849563
[No Abstract] [Full Text] [Related]
3. Properdin binding to complement activating surfaces depends on initial C3b deposition.
Harboe M; Johnson C; Nymo S; Ekholt K; Schjalm C; Lindstad JK; Pharo A; Hellerud BC; Nilsson Ekdahl K; Mollnes TE; Nilsson PH
Proc Natl Acad Sci U S A; 2017 Jan; 114(4):E534-E539. PubMed ID: 28069958
[TBL] [Abstract][Full Text] [Related]
4. Opsonophagocytosis of Chlamydia pneumoniae by Human Monocytes and Neutrophils.
Lausen M; Pedersen MS; Rahman NSK; Holm-Nielsen LT; Farah FYM; Christiansen G; Birkelund S
Infect Immun; 2020 Jun; 88(7):. PubMed ID: 32284372
[TBL] [Abstract][Full Text] [Related]
5. An evaluation of the role of properdin in alternative pathway activation on Neisseria meningitidis and Neisseria gonorrhoeae.
Agarwal S; Ferreira VP; Cortes C; Pangburn MK; Rice PA; Ram S
J Immunol; 2010 Jul; 185(1):507-16. PubMed ID: 20530262
[TBL] [Abstract][Full Text] [Related]
6. Identification of a novel mode of complement activation on stimulated platelets mediated by properdin and C3(H2O).
Saggu G; Cortes C; Emch HN; Ramirez G; Worth RG; Ferreira VP
J Immunol; 2013 Jun; 190(12):6457-67. PubMed ID: 23677468
[TBL] [Abstract][Full Text] [Related]
7. The Role of Properdin in Killing of Non-Pathogenic
Martinez APG; Abreu PAE; de Arruda Vasconcellos S; Ho PL; Ferreira VP; Saggu G; Barbosa AS; Isaac L
Front Immunol; 2020; 11():572562. PubMed ID: 33240263
[TBL] [Abstract][Full Text] [Related]
8. The role of properdin in the assembly of the alternative pathway C3 convertases of complement.
Hourcade DE
J Biol Chem; 2006 Jan; 281(4):2128-32. PubMed ID: 16301317
[TBL] [Abstract][Full Text] [Related]
9. Analysis of the interactions between properdin, the third component of complement (C3), and its physiological activation products.
Farries TC; Lachmann PJ; Harrison RA
Biochem J; 1988 May; 252(1):47-54. PubMed ID: 3421908
[TBL] [Abstract][Full Text] [Related]
10. Properdin in complement activation and tissue injury.
Lesher AM; Nilsson B; Song WC
Mol Immunol; 2013 Dec; 56(3):191-8. PubMed ID: 23816404
[TBL] [Abstract][Full Text] [Related]
11. The role of properdin in zymosan- and Escherichia coli-induced complement activation.
Harboe M; Garred P; Lindstad JK; Pharo A; Müller F; Stahl GL; Lambris JD; Mollnes TE
J Immunol; 2012 Sep; 189(5):2606-13. PubMed ID: 22851705
[TBL] [Abstract][Full Text] [Related]
12. Role of properdin in complement-mediated kidney diseases.
van Essen MF; Ruben JM; de Vries APJ; van Kooten C;
Nephrol Dial Transplant; 2019 May; 34(5):742-750. PubMed ID: 30053164
[TBL] [Abstract][Full Text] [Related]
13. Chlamydia pneumoniae infection: which role in atherosclerosis?
Gabrielli M; Santarelli L; Gasbarrini A
Arch Intern Med; 2002 Oct; 162(18):2140; author reply 2141. PubMed ID: 12374525
[No Abstract] [Full Text] [Related]
14. Properdin binds to late apoptotic and necrotic cells independently of C3b and regulates alternative pathway complement activation.
Xu W; Berger SP; Trouw LA; de Boer HC; Schlagwein N; Mutsaers C; Daha MR; van Kooten C
J Immunol; 2008 Jun; 180(11):7613-21. PubMed ID: 18490764
[TBL] [Abstract][Full Text] [Related]
15. Initial properdin binding contributes to alternative pathway activation at the surface of viable and necrotic cells.
van Essen MF; Schlagwein N; van den Hoven EMP; van Gijlswijk-Janssen DJ; Lubbers R; van den Bos RM; van den Born J; Ruben JM; Trouw LA; van Kooten C;
Eur J Immunol; 2022 Apr; 52(4):597-608. PubMed ID: 35092629
[TBL] [Abstract][Full Text] [Related]
16. The sst1 resistance locus regulates evasion of type I interferon signaling by Chlamydia pneumoniae as a disease tolerance mechanism.
He X; Berland R; Mekasha S; Christensen TG; Alroy J; Kramnik I; Ingalls RR
PLoS Pathog; 2013; 9(8):e1003569. PubMed ID: 24009502
[TBL] [Abstract][Full Text] [Related]
17. Chlamydia pneumoniae and atherosclerosis.
Grayston JT
Clin Infect Dis; 2005 Apr; 40(8):1131-2. PubMed ID: 15791512
[No Abstract] [Full Text] [Related]
18. Aurin tricarboxylic acid self-protects by inhibiting aberrant complement activation at the C3 convertase and C9 binding stages.
Lee M; Guo JP; McGeer EG; McGeer PL
Neurobiol Aging; 2013 May; 34(5):1451-61. PubMed ID: 23177218
[TBL] [Abstract][Full Text] [Related]
19. Recruitment of properdin by bi-specific nanobodies activates the alternative pathway of complement.
Pedersen DV; Rösner T; Hansen AG; Andersen KR; Thiel S; Andersen GR; Valerius T; Laursen NS
Mol Immunol; 2020 Aug; 124():200-210. PubMed ID: 32599335
[TBL] [Abstract][Full Text] [Related]
20. Inclusion fluorescent-antibody test as a screening assay for detection of antibodies to Chlamydia pneumoniae.
Tapia O; Slepenkin A; Sevrioukov E; Hamor K; de la Maza LM; Peterson EM
Clin Diagn Lab Immunol; 2002 May; 9(3):562-7. PubMed ID: 11986260
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
